Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-9.17%
$21.76
0% positive prob.
5-Day Prediction
-10.92%
$21.34
0% positive prob.
20-Day Prediction
+424.71%
$125.72
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q1 2026 | SELL | -9.17% | -10.92% | +424.71% | 100.0% | Pending |
| Q3 2025 | BUY | +4.64% | +35.74% | +72.43% | 100.0% | +29.38% |
SEC 8-K filings with transcript text
May 14, 2026 · 100% conf.
1D
-9.17%
$21.76
5D
-10.92%
$21.34
20D
+424.71%
$125.72
2 d95486dex991.htm
Exhibit 99.1
FORTE BIOSCIENCES, INC. ANNOUNCES FIRST QUARTER 2026 RESULTS AND PROVIDES UPDATE
FB102 Received Fast Track Designation in Celiac Disease
DALLAS, TX – MAY 11, 2026 – Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2026 financial results and provided a business update.
“FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need and reinforcing FB102’s potential to address the high unmet need in celiac disease. The clinical development for FB102 continues to progress well with important readouts coming shortly,” said Forte Biosciences CEO Paul Wagner, PhD. “The topline results from our phase 2 celiac disease study are expected in 2026. Based on the strength of the positive results from the FB102 phase 1b CeD trial, which we reported in June 2025, we look forward to the phase 2 data further validating FB102 for the treatment of celiac disease. The FB102 phase 1b vitiligo clinical study is expected to have topline results shortly and the alopecia areata phase 1b data readout is expected in 2026. We remain very optimistic about FB102’s potential to address the significant unmet medical needs across multiple indications representing what we believe to be multi-billion-dollar potential market opportunities.”
Q1 2026 Operating Results
Research and development expenses were $20.5 million for the three months ended March 31, 2026, compared to $12.7 million for the same period in 2025. The increase was primarily due to an increase of $6.7 million in clinical expenses related to FB102 for our Phase 2 clinical trial for celiac disease and Phase 1b clinical trials for vitiligo and alopecia areata, an increase of $2.0 million in preclinical expenses, and an increase of $1.4 million in personnel-related expenses due to an increase in headcount, partially offset by a decrease of $2.3 million in manufacturing expenses.
Our research and development expenses may increase as we continue to advance FB102 through a celiac Phase 2 trial including a U.S. arm, multiple Phase 1b clinical trials and if we pursue additional autoimmune indications.
General and administrative expenses were $2.0 million for the three months ended March 31, 2026 compared to $3.4 million for the same period in 2025. The decrease was primarily due to the interim legal settlement payment, under a reservation of rights from an insurance carrier of $2.3 million, partially offset by an increase of $0.9 million in non-cash stock-based compensation.
Our general and administrative expenses may fluctuate in the future due to fluctuations in professional and advisory fees as we build out our infrastructure to advance FB102 through a Phase 2 trial, multiple Phase 1b clinical trials and if we pursue additional autoimmune indications.
Net losses per share were $(1.24) and $(1.37) for the quarters ended March 31, 2026 and 2025, respectively.
Forte ended the first quarter of 2026 with $58.2 million in cash and cash equivalents. There are 13.9 million shares of common stock and 4.0 million prefunded warrants outstanding as of March 31, 2026. In April 2026, Forte raised $172.5 million in gross proceeds through an offering and issued 6.6 million additional shares of common stock.
(in thousands, except share and par value data)
March 31, 2026
December 31, 2025
(unaudited)
Assets
Current assets:
Cash and cash equivalents
$ 58,223
$ 76,957
Prepaid expenses and other current assets
6,887
3,632
Total current assets
65,110
80,589
Property and equipment, net
110
129
Other assets
2,003
2,061
Total assets
$ 67,223
$ 82,779
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
$ 13,084
$ 9,989
Accrued liabilities
10,563
10,762
Total current liabilities
23,647
20,751
Other liabilities
1,476
1,037
Total liabilities
25,123
21,788
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, $0.001 par value: 200,000,000 shares authorized as of March 31, 2026 (unaudited) and December 31, 2025; 13,910,668 and 12,948,308 shares issued and outstanding as of March 31, 2026 (unaudited) and December 31, 2025, respectively
14
13
Additional paid-in capital
287,599
284,348
Accumulated other comprehensive (loss) income
(4 )
3
Accumulated deficit
(245,509 )
(223,373 )
Total stockholders’ equity
42,100
60,991
Total liabilities and stockholders’ equity
$ 67,223
$ 82,779
(unaudited)
(in thousands, except share and per share amounts)
For the Three Months Ended March 31,
2026
2025
Operating expenses:
Research and development
$ 20,320
$ 12,542
Research and development - related party
150
150
Ge
Apr 1, 2026 · 100% conf.
1D
-9.17%
$21.76
5D
-10.92%
$21.34
20D
+424.71%
$125.72
2 d63145dex991.htm
Exhibit 99.1
DALLAS, TX – MARCH 31, 2026 – Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its full year 2025 financial results and provided a business update.
“The clinical development for FB102 continues to progress well with important readouts in 2026.” said Forte Biosciences CEO Paul Wagner, PhD. “The topline results from our phase 2 celiac disease study is expected in 2026. Based on the strength of the positive results from the FB102 phase 1b CeD trial, which we reported in June 2025, we look forward to the phase 2 data further validating FB102 for the treatment of celiac disease. The FB102 phase 1b vitiligo clinical study is expected to have topline results in 1H 2026 and the alopecia areata phase 1b data readout is expected in 2026. This will be a very eventful year and further highlight FB102’s potential to address the significant unmet medical needs across multiple indications representing multi-billion dollar potential market opportunities.”
2025 Operating Results
Research and development expenses were $58.2 million for the year ended December 31, 2025, compared to $21.2 million during the same period in 2024. The increase was primarily due to an increase of $36 million in manufacturing and clinical expenses related to FB102 for our Phase 2 clinical trial for celiac disease and Phase 1b clinical trials for vitiligo and alopecia areata, an increase of $0.4 million in discovery work, and an increase of $1.9 million in personnel-related expenses due to an increase in headcount, partially offset by a decrease of $1.5 million in preclinical expenses as a result of toxicology work performed in 2024.
Our research and development expenses may increase as we continue to advance FB102 through a celiac Phase 2 trial including a U.S. arm as a result of the FDA approving our IND, multiple Phase 1b clinical trials and if we pursue additional autoimmune indications.
General and administrative expenses were $12.4 million for the year ended December 31, 2025 compared to $15.4 million for the same period in 2024. The decrease was primarily due to decreases in professional and legal advisory fees, including litigation and settlement expenses, of $6.1 million, partially offset by an increase of $3.0 million in personnel-related expenses, including additional non-cash stock-based compensation of $2.5 million.
Our general and administrative expenses may fluctuate in the future due to fluctuations in professional and advisory fees as we build out our infrastructure to advance FB102 through a Phase 2 trial, multiple Phase 1b clinical trials and if we pursue additional autoimmune indications.
Net losses per share were $(4.71) and $(12.17) for the year ended December 31, 2025 and 2024, respectively.
Forte ended the fourth quarter of 2025 with $77.0 million in cash and cash equivalents. There are 12.9 million shares of common stock and 4.9 million prefunded warrants outstanding as of December 31, 2025.
Forte Biosciences, Inc.
Consolidated Balance Sheets
(in thousands, except share and par value data)
December 31, 2025
December 31, 2024
Assets
Current assets:
Cash and cash equivalents
$ 76,957
$ 22,244
Short-term investment
—
36,121
Prepaid expenses and other current assets
3,632
2,981
Total current assets
80,589
61,346
Property and equipment, net
129
77
Other assets
2,061
138
Total assets
$ 82,779
$ 61,561
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
$ 9,989
$ 4,879
Accrued liabilities
10,762
4,202
Total current liabilities
20,751
9,081
Income tax payable
1,037
—
Total liabilities
21,788
9,081
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, $0.001 par value: 200,000,000 share, authorized as of December 31, 2025 and December 31, 2024; 12,948,308 and 6,393 ,323 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively
13
6
Additional paid-in capital
284,348
206,461
Accumulated other comprehensive income
3
11
Accumulated deficit
(223,373 )
(153,998 )
Total stockholders’ equity
60,991
52,480
Total liabilities and stockholders’ equity
$ 82,779
$ 61,561
Forte Biosciences, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
Year Ended December 31,
2025
2024
Operating expenses:
Research and development
$ 57,647
$ 20,714
Research and development - related party
600
479
General and administrative
12,410
15,409
Total operating expenses
70,657
36,602
Loss from operations
(70,657 )
(36,602 )
Interest income
2,715
1,314
Other expense, net
(396 )
(190 )
Total other income, net
2,319
1,124
Net loss before taxes
(68,338 )
(35,478 )
Income tax expense
1
Nov 14, 2025 · 100% conf.
1D
+4.64%
$15.05
Act: +0.76%
5D
+35.74%
$19.52
Act: +29.38%
20D
+72.43%
$24.80
8-K
false 0001419041 0001419041 2025-11-14 2025-11-14
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-38052
26-1243872
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
3060 Pegasus Park Dr. Building 6 Dallas, Texas
75247
(Address of Principal Executive Offices)
(Zip Code) Registrant’s Telephone Number, Including Area Code: (310) 618-6994 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 14, 2025, Forte Biosciences, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Description
99.1
Press Release dated November 14, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 14, 2025
By:
/s/ Antony Riley
Antony Riley Chief Financial Officer
This page provides Forte Biosciences Inc. (FBRX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on FBRX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.